GHRS

GH Research Reports Full Year 2023 Financial Results and Provides Business Updates

Retrieved on: 
Thursday, February 29, 2024
PD, Research, New Drug Application, TRD, GHRS, FDA, BDII, Food, EPO, Rat, Psychiatry, Patent, PPD, Patient, IDR, DSM-IV codes, Clinical trial, Insurance, Psychotherapy, G&A, MDD, IND, European Patent Convention, Pharmaceutical industry

DUBLIN, Ireland, Feb. 29, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the year ended December 31, 2023, and provided updates on its business.

Key Points: 
  • DUBLIN, Ireland, Feb. 29, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the year ended December 31, 2023, and provided updates on its business.
  • As announced in November 2023, both trials were recruiting slower than anticipated, in part due to the closure, for business reasons, of one of the two sites activated in each trial.
  • Subsequently, we have implemented measures to strengthen recruitment of both trials, including the addition of further clinical trial sites.
  • For the trial in patients with PPD (GH001-PPD-203), we now expect completion and availability of top-line data in the third quarter of 2024.

GH Research Announces Grant of European Patent Covering all Mebufotenin (5-MeO-DMT) and Mebufotenin Salt Products For Use in the Treatment of Major Depressive Disorder and Treatment-Resistant Depression

Retrieved on: 
Thursday, January 18, 2024
DSM-IV codes, European Patent Convention, Patient, EPO, IP, Psychiatry, Communication, TRD, MDD, Patent, Research, GHRS, Pharmaceutical industry

It is therefore expected to effectively fortify the company’s position at the forefront of novel rapid-acting antidepressant treatments.

Key Points: 
  • It is therefore expected to effectively fortify the company’s position at the forefront of novel rapid-acting antidepressant treatments.
  • Theis Terwey, CEO and Co-founder of GH Research said: “We are committed to providing highly effective new therapies to patients in mental health care who are underserved by existing treatments.
  • Having a strong IP portfolio helps us with this mission, and it is satisfying to have the EPO endorse the strength of our IP.
  • We feel well placed to progress the rest of our patent portfolio through the examination process in Europe, the US and beyond, and are looking forward to exploring additional opportunities with mebufotenin through continuous research and development.”

GH Research Reports Third Quarter Financial Results and Provides Business Updates

Retrieved on: 
Thursday, November 9, 2023
Feedback, Food, IND, Clinical trial, DSM-IV codes, Insurance, Patient, Research, FDA, GHRS, G&A, New Drug Application, Histology, TRD, Psychiatry, Rat, Letter, Pharmaceutical industry, Cryptocurrency

DUBLIN, Ireland, Nov. 09, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the third quarter ended September 30, 2023, and provided business updates.

Key Points: 
  • DUBLIN, Ireland, Nov. 09, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the third quarter ended September 30, 2023, and provided business updates.
  • R&D expenses were $7.1 million for the quarter ended September 30, 2023, compared to $4.6 million for the same quarter in 2022.
  • G&A expenses were $2.6 million for the quarter ended September 30, 2023, compared to $2.0 million for the same quarter in 2022.
  • Recently, the clinical research organization that manages one of our clinical trial sites informed us that the site will be closed for business reasons.

GH Research Provides Updates and Guidance on its Clinical Development Program for GH001 in Treatment-Resistant Depression

Retrieved on: 
Friday, September 29, 2023
Psychiatry, IDR, New Drug Application, GHRS, DSM-IV codes, CFR, MADRS, Patient, Grammatical mood, Research, FDA, Letter, TRD, IND, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Pharmaceutical industry, European

DUBLIN, Ireland, Sept. 29, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today provided updates and guidance on its clinical development program for GH001, its proprietary inhalable mebufotenin (5-MeO-DMT) product candidate, in treatment-resistant depression (TRD).

Key Points: 
  • DUBLIN, Ireland, Sept. 29, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today provided updates and guidance on its clinical development program for GH001, its proprietary inhalable mebufotenin (5-MeO-DMT) product candidate, in treatment-resistant depression (TRD).
  • The double-blind phase is followed by a 6-month open-label extension phase where all patients can receive treatment with the GH001 IDR as-needed, based on the patient’s clinical status.
  • We are awaiting that follow-up letter from the FDA and look forward to working with them to resolve any outstanding concerns.
  • We plan to provide an update in our next earnings release in November 2023.

GH Research Reports Second Quarter 2023 Financial Results and Provides Business Updates

Retrieved on: 
Wednesday, August 23, 2023
Psychiatry, Insurance, IDR, Medical Affairs Bureau, Ipsen, Clinical trial, GHRS, DSM-IV codes, G&A, MADRS, Bipolar II disorder, Acquisition, Patient, Master of Science, Grammatical mood, Albireo, Research, FDA, TRD, IND, Pharmaceutical industry, Cryptocurrency, MD, Sanofi

DUBLIN, Ireland, Aug. 23, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the second quarter ended June 30, 2023 and provided business updates.

Key Points: 
  • DUBLIN, Ireland, Aug. 23, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the second quarter ended June 30, 2023 and provided business updates.
  • R&D expenses were $7.2 million for the quarter ended June 30, 2023, compared to $4.2 million for the same quarter in 2022.
  • G&A expenses were $2.7 million for the quarter ended June 30, 2023, compared to $2.5 million for the same quarter in 2022.
  • The net profit in the prior year quarter was due to a foreign exchange gain which was not repeated in 2023.

GH Research Reports First Quarter 2023 Financial Results and Provides Business Highlights

Retrieved on: 
Thursday, May 11, 2023
Psychiatry, Insurance, IDR, Inhalation, GHRS, DSM-IV codes, G&A, MADRS, Bipolar II disorder, Patient, Grammatical mood, Research, TRD, IND, Pharmaceutical industry, Cryptocurrency

DUBLIN, Ireland, May 11, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the first quarter ended March 31, 2023 and provided business highlights.

Key Points: 
  • DUBLIN, Ireland, May 11, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the first quarter ended March 31, 2023 and provided business highlights.
  • R&D expenses were $7.3 million for the quarter ended March 31, 2023, compared to $4.7 million for the same quarter in 2022.
  • G&A expenses were $3.1 million for the quarter ended March 31, 2023, compared to $3.3 million for the same quarter in 2022.
  • As previously announced, we expect to submit an IND for GH001 in TRD, delivered with our proprietary aerosol delivery device, in the third quarter of 2023.

GH Research Reports Full Year 2022 Financial Results and Provides Business Updates

Retrieved on: 
Thursday, March 2, 2023
Inhalation, Insurance, MADRS, World Health Organization, Psychiatry, INN, The International Pharmacopoeia, DSM-IV codes, Patient, WHO, Patent, Research, International, G&A, GHRS, IDR, TRD, Grammatical mood, IND, Pharmaceutical industry, Cryptocurrency

DUBLIN, Ireland, March 02, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the full year ended December 31, 2022 and gave updates on its business.

Key Points: 
  • DUBLIN, Ireland, March 02, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the full year ended December 31, 2022 and gave updates on its business.
  • R&D expenses were $20.5 million for the year ended December 31, 2022, compared to $8.6 million for the full year 2021.
  • G&A expenses were $10.1 million for the year ended December 31, 2022, compared to $6.5 million for the full year 2021.
  • The increase was primarily due to higher insurance costs, an increase in professional costs as well as increased employee expenses.

GH Research Provides Business Updates and Highlights Key Upcoming Milestones

Retrieved on: 
Monday, January 9, 2023
IND, Inhalation, World Health Organization, The International Pharmacopoeia, WHO, TRD, International, Research, GHRS, Psychiatry, Patent, INN, Pharmaceutical industry

We have recently received initial regulatory and ethical approvals for our planned multi-center, randomized, double-blind, placebo-controlled Phase 2b trial of GH001 in treatment-resistant depression (TRD) (GH001-TRD-201).

Key Points: 
  • We have recently received initial regulatory and ethical approvals for our planned multi-center, randomized, double-blind, placebo-controlled Phase 2b trial of GH001 in treatment-resistant depression (TRD) (GH001-TRD-201).
  • We continue to expect initiation of this trial in several European countries in the first quarter of 2023.
  • Trial design details are described in our updated corporate presentation, which is available in the investor section on our website.
  • The previously announced randomized, double-blind, placebo-controlled, dose-ranging clinical pharmacology trial of GH002 in healthy volunteers (GH002-HV-105) has recently been initiated.

GH Research Reports Third Quarter 2022 Financial Results and Provides Business Updates

Retrieved on: 
Thursday, November 10, 2022
GLOBE, BDII, Forward-looking statement, IND, Form 20-F, Nasdaq, Food, TRD, PPD, IDR, Annual report, Research, MADRS, Postpartum depression, Bipolar II disorder, G&A, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, 5-Methoxy-N,N-diisopropyltryptamine, Psychiatry, U.S. Securities and Exchange Commission, Grammatical mood, Clinical trial, Patient, GHRS, Insurance, FDA, Pharmaceutical industry

DUBLIN, Ireland, Nov. 10, 2022 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the third quarter ended September 30, 2022 and gave updates on its business.

Key Points: 
  • DUBLIN, Ireland, Nov. 10, 2022 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the third quarter ended September 30, 2022 and gave updates on its business.
  • Cash was $256.9 million as of September 30, 2022, compared to $276.8 million as of December 31, 2021.
  • R&D expenses were $4.6 million for the quarter ended September 30, 2022, compared to $2.6 million for the same quarter in 2021.
  • G&A expenses were $2.0 million for the quarter ended September 30, 2022, compared to $2.1 million for the same quarter in 2021.

GH Research Reports Second Quarter 2022 Financial Results and Provides Business Updates

Retrieved on: 
Tuesday, August 23, 2022
Research, Psychiatry, IND, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Insurance, Lists of diseases, Postpartum depression, Food, Grammatical mood, U.S. Securities and Exchange Commission, Bipolar II disorder, GLOBE, IDR, 5-Methoxy-N,N-diisopropyltryptamine, Nasdaq, FDA, TRD, GHRS, G&A, Clinical trial, Annual report, Form 20-F, BDII, Forward-looking statement, PPD, Patient, MADRS, Pharmaceutical industry

DUBLIN, Ireland, Aug. 23, 2022 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the second quarter ended June 30, 2022 and gave updates on its business.

Key Points: 
  • DUBLIN, Ireland, Aug. 23, 2022 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the second quarter ended June 30, 2022 and gave updates on its business.
  • Cash was $265.4 million as of June 30, 2022, compared to $276.8 million as of December 31, 2021.
  • R&D expenses were $4.2 million for the quarter ended June 30, 2022, compared to $2.0 million for the same quarter in 2021.
  • G&A expenses were $2.5 million for the quarter ended June 30, 2022, compared to $0.7 million for the same quarter in 2021.